Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics is a clinical-stage precision medicine company that uses its Dynamo platform to integrate leading-edge computational and experimental approaches for previously untreatable targets. Its initial efficacy data from the dose-escalation study showed a best-in-class safety profile, with a 44% objective response rate and a 77% patient retention rate. With a focus on precision oncology and genetic disease, RLAY has potential for substantial growth in the coming years.

Bears say

Relay Therapeutics is predicted to be a leader in precision medicine, developing a strong pipeline of first-in-class medicines for precision oncology and genetic diseases. However, their early triplet update exhibits superior results compared to their competitors, potentially increasing opportunity in 1L HR+/HER2- metastatic breast cancer and potentially mitigating the risk of their ongoing ReDiscover-2 trial. Furthermore, their sales and marketing and deemed dividend expenses could potentially impact the company's financials and overall outlook.

RLAY has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 9 analysts, RLAY has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.